ERBB2 and cancer: The three ADCs differ for structural features and targets: T‐DM1 combines trastuzumab, a HER2‐targeted monoclonal antibody, with the microtubule inhibitor DM1, offering selective cytotoxicity in HER2‐positive cancers.